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Introduction: Acute coronary syndrome is one of the most frequent medical emergencies in developing 
countries.
Objective: To determine, from the perspective of the Colombian health system, the cost-effectiveness 
of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome. 
Materials and methods: We conducted a cost-effectiveness analysis from the perspective of the 
Colombian health system comparing ticagrelor and clopidogrel for the treatment of patients with acute 
coronary syndrome. To estimate the expected costs and outcomes, a Markov model was constructed 
in which patients could remain stable without experiencing new cardiovascular events, suffer from 
a new event, or die. For the baseline case, a 10-year time horizon and a discount ratio of 3% for 
costs and benefits were adopted. The transition probabilities were extracted from the PLATO (Platelet 
Inhibition and Patient Outcomes) clinical trial. Vital statistics were drawn from the Departmento 
Administrativo Nacional de Estadística (DANE) and additional information from Colombian patients 
included in the Access registry. To identify and measure resource use, a standard case was built by 
consulting guidelines and protocols. Unit costs were obtained from Colombian rate lists. A probabilistic 
sensitivity analysis was conducted in which costs were represented by a triangular distribution, and the 
effectiveness through a beta distribution.
Results: In the base case, the additional cost per quality-adjusted life-year gained with ticagrelor 
was COP$ 28,411,503. The results were sensitive to changes in the time horizon and the unit cost of 
clopidogrel. For a willingness-to-pay equivalent to three times the Colombian per capita gross domestic 
product, the probability of ticagrelor being cost-effective was 75%. 
Conclusions: Ticagrelor is a cost-effective strategy for the treatment of patients with acute coronary 
syndrome in Colombia.
Key words: Acute coronary syndrome; economics, medical; health economics, costs and cost analysis, 
evaluation studies as topic, Colombia. 
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Análisis de costo-efectividad del ticagrelor en comparación con el clopidogrel para el tratamiento 
de pacientes con síndrome coronario agudo en Colombia
Introducción. El síndrome coronario agudo es una de las emergencias médicas más frecuentes en 
los países en desarrollo.
Objetivo. Determinar, desde la perspectiva del sistema de salud colombiano, la relación de costo-
efectividad del ticagrelor comparado con el clopidogrel para el tratamiento de pacientes con síndrome 
coronario agudo.
532
Biomédica 2015;35:531-40Mejía A, Senior JM, Ceballos M, et al.
Materiales y métodos. Se hizo un análisis de costo-efectividad desde la perspectiva del sistema 
de salud colombiano, comparando el ticagrelor y el clopidogrel para el tratamiento de pacientes con 
síndrome coronario agudo. Para estimar los costos y resultados esperados de las dos alternativas, se 
construyó un modelo de Markov en el cual los pacientes podían permanecer estables sin experimentar 
nuevos eventos cardiovasculares, sufrir de un nuevo evento coronario o morir. Para el caso de base, se 
adoptó un horizonte temporal de 10 años y una tasa de descuento de 3 % para los costos y beneficios. 
Las probabilidades de transición se extrajeron del estudio Platelet Inhibition and Patient Outcomes, 
PLATO. Las estadísticas vitales se consultaron en informes del Departamento Administrativo Nacional 
de Estadística (DANE) y los parámetros adicionales del modelo se basaron en la información de los 
pacientes colombianos incluidos en el registro en Access. Para identificar y medir el uso de recursos, 
se construyó un caso estándar a partir de guías y protocolos. Los costos unitarios se obtuvieron de 
manuales tarifarios colombianos. Se hizo un análisis de sensibilidad probabilístico en el que los costos 
se representaron por una distribución triangular y, las probabilidades de transición, mediante una 
distribución beta.
Resultados. En el caso de base, el costo adicional por años de vida ajustados por calidad ganados con 
el ticagrelor fue de COP$ 28’411.503. Los resultados fueron sensibles a los cambios en el horizonte 
temporal y al costo unitario del clopidogrel. Para un umbral de costo-efectividad equivalente a tres 
veces el producto interno bruto per cápita de Colombia, la probabilidad de que el ticagrelor fuera costo-
efectivo fue de 75 %.
Conclusiones. El ticagrelor es una estrategia costo-efectiva para el tratamiento de los pacientes con 
síndrome coronario agudo en Colombia.
Palabras clave: síndrome coronario agudo, economía médica, economía de la salud, costos y análisis 
de costo, estudios de evaluación como tema, Colombia.
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The acute coronary syndrome is one of the most 
frequent medical emergencies in developing 
countries and one of the most prevalent manifes-
tations of cardiovascular disease (1). In Colombia, 
according to the vital statistics 2007-2008 issued 
by the Departamento Administraivo Nacional 
de Estadística (DANE) (2), the rate of mortality 
from ischemic heart disease during this time 
period among 45-year old and older adults was 
263.7/100,000. Life expectancy in the Colombian 
population is projected to increase from 67.8 
years during 1985-1990 period to 73.9 years in 
2010-2015. Thus, during this time the population 
older than 45 will triple leading to an increase in 
the incidence and prevalence of atherosclerotic 
cardiac disease and, by consequence, an increase 
in the cost of health care. According to statistics 
published by DANE, and based on the international 
disease classification CIE-10, ischemic cardiac 
disease was the leading cause of death in persons 
55 and older, surpassing cancer and violence. The 
high morbidity and mortality of this illness pose 
an important challenge given its impact on health 
status, quality of life, and on social, labour and 
economic indicators.
The acute coronary syndrome has high social costs 
due to the treatment and the loss of productivity 
among those who experience an event. Multiple 
studies have been conducted to determine the most 
cost-effective treatment and its optimal duration, 
and have found that individuals who receive 
standard treatment with aspirin after an acute 
coronary event remain at high risk of experiencing 
coronary events in the short and long term (3-6). 
Therefore, medications such as clopidogrel have 
been developed that, when added to conventional 
treatment with aspirin, improve the patient’s quality 
of life and reduce the risk of new cardiovascular 
events (7,8). Recently, new medications have 
been introduced for dual therapy use, such as 
ticagrelor (9), which has demonstrated increased 
effectiveness as compared with aspirin plus 
clopidogrel, but with high costs.
The high effectiveness but high cost of ticagrelor 
poses a dilemma regarding which alternative 
should be implemented in the Colombian health 
system to achieve the highest benefits to health 
while taking into account the budgetary restrictions 
in the country. Therefore, the objective of this 
article was to evaluate, from the perspective of the 
Colombian health system, the cost-effectiveness of 
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aspirin plus ticagrelor treatment compared to aspirin 
plus clopidogrel for patients with acute coronary 
syndrome in Colombia. This study was performed 
during the development of the Colombian guideline 
for patients with acute coronary syndrome (1), and it 
was an input that the guideline development group 
took into consideration when they were generating 
recommendations about optimal medical treatment 
for patients with acute coronary syndrome.
Materials and methods
We developed a cost-effectiveness analysis from 
the perspective of the Colombian health system 
(i.e., only direct medical costs and health benefits 
perceived by patients were considered). The popu-
lation consisted of 18-year old or older patients 
with acute coronary syndrome, with or without ST 
segment elevation (9). 
The alternatives evaluated were:
1. Aspirin plus clopidogrel, which is the strategy 
contemplated in the current protocol of the 
Colombian health system, with an initial dose of 
clopidogrel of 300 mg, and then 75 mg per day 
for a year.
2. Aspirin plus ticagrelor (new treatment), with an 
initial dose of ticagrelor of 180 mg, and then 90 mg 
twice a day for a year.
From here on, clopidogrel or ticagrelor treatment 
should be understood to mean dual antiplatelet 
therapy. We included these alternatives because 
they were those evaluated by the guideline devel-
opment group to be incorporated in the clinical 
guideline for adults with acute coronary syndrome 
(1). Another antiplatelet available (prasugrel) is not 
considered in the analysis given the absence of 
head-to-head trial data (and even credible indirect 
evidence) comparing ticagrelor to prasugrel at the 
time this analysis was performed. 
The natural history of the disease goes through 
different stages including acute events such as 
myocardial infarction, stroke, and death, as well 
as non-fatal health outcomes (1). We considered, 
therefore, that a Markov model could be useful to 
represent the natural history of the acute coronary 
syndrome and estimate the expected cost and 
effectiveness of both interventions. During the first 
year, four possible outcomes were considered: 
myocardial infarction, stroke, no event, and death. 
Patients who experienced a myocardial infarction 
or stroke could die or progress to the post-
myocardial infarction or post-stroke stage. These 
two last stages enabled us to capture the costs 
and outcomes of the patients who experienced a 
non-fatal event during the first year of follow-up or 
in one of the following years. 
The model is depicted in figure 1. In the base 
case analysis, patients who experience either a 
myocardial infarction or stroke progress to post-
myocardial infarction, post-stroke, or death. 
However, it is possible that a patient who 
experiences a myocardial infarction or stroke 
during the first year will experience a new event in 
following years. Therefore, to take this possibility 
into account, we performed a sensitivity analysis 
in which the structure of the model was modified 
to include the probability of experiencing new 
coronary events in the long term.
The “no event” stage captured the patients who did 
not experience a new event. The simulation was 
set up such that the patients that remained in this 
stage were at risk of experiencing new events. 
Taking published models into account and the fact 
that relevant clinical trials had a <1-year follow up, 
we assumed that no differences existed between 
the risks of any of these events after the first year. 
This meant that the effect of the long-term strategies 
was fundamentally determined by the effects the 
strategies had on the outcomes in the first year.
To estimate the effectiveness of ticagrelor, a 
systematic review was conducted by searching 
Medline (PubMed) (see search strategy in table 
1). The search did not yield any systematic 
reviews, and only one clinical trial was found that 
compared ticagrelor to clopidogrel for treatment of 
acute coronary syndrome patients (9). This article 
was considered of high quality according to the 
guideline development group (1). From that study 
we estimated the probabilities of the different 
events in the model during the first year. The 
probability of death (adjusted for age) was based 
on vital statistics from DANE. The risk of new 
coronary events in the long term was estimated 
using the information from Colombian patients 
included in the Access registry.
The main outcome of this analysis was the quality-
adjusted life-year (QALY). Utility weights for each 
outcome were derived from the PLATO HECON 
study (10) (the data used correspond to the general 
average of all countries; although Colombian 
patients participated in this study, no disaggregated 
data by country were available) (table 2). Given that 
death is not the only event of interest and quality 
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of life after non-fatal events is a critical outcome, the 
QALY is an appropriate outcome for the analysis as 
it allows combining the effect of the interventions 
on both the length and quality of life.
To estimate the cost of each health outcome we 
identified the resources with the highest expected 
impact on total costs and therefore the highest 
probability of influencing the decision, such as 
hospitalization in the intensive care unit, the 
type of stent (drug-eluting or bare metal stent) 
for the percutaneous coronary intervention, 
cardiac rehabilitation programs, and medications, 
among others. Resource use was quantified by 
constructing a standard case based on the review 
of clinical practice guidelines and hospital protocols 
from a Colombian teaching hospital in Medellín. 
These results were discussed with various internal 
medicine and cardiology experts, and through 
informal consensus the frequency for each item 
was estimated. Details of the resources included, 
unit of measurement and frequency can be found 
in the clinical practice guideline (1).
The unit cost of medication (table 3) was obtained 
from the Colombian system of information of 
medication prices (SISMED) (11). The unit cost 
corresponds to the weighted price (according to 
number of units sold) for the different presentations 
in the Colombian market, including generic as 
well as brand name version of the medications. 
To estimate unit cost of medical and surgical 
procedures, a survey was administered to various 
Colombian health insurance companies to identify 
the fees manuals most used to hire providers. From 
this consultation, we determined that the different 
manuals could be equated to the values reported 
in the 2001 fees manual of the former Instituto de 
Seguro Social (ISS) plus 30%, with a minimum 
percentage of 25% and a maximum of 48%. Finally, 
No event
No event
MI
MI
Stroke
Stroke
Clopidogrel
Ticagrelor
ACS patients
Death
Death
Death
Death
Death
Post-MI
Post-MI
Post-MI
Post-stroke
Post-stroke
Death
Post-stroke
+M
M
Figure 1. Decision model for the comparison between ticagrelor and clopidogrel
Table 1. Medline search strategy using PubMed (Date of search: February, 2012)
(Acute Coronary Syndrome[Mesh] OR Acute Coronar*[tiab] OR Coronary Syndrom*[tiab] OR STEMI[tiab] OR non-STEMI[tiab]) 
AND (systematic review[tiab] OR Meta-Analysis[pt] OR Meta-Analysis as Topic[mh] OR Meta-Analys*[tiab] OR “Cochrane 
Database Syst Rev”[Journal:__jrid21711]) AND (Aspirin[Mesh] OR Acetylsalicylic Acid[tiab] OR aspirin*[tiab] OR ASA[tiab]) AND 
(clopidogrel[all] OR ticagrelor [all])
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for medical supplies, information provided by a 
level 3 hospital in the city of Medellín was used. All 
prices are given in 2010 Colombian pesos, as they 
represent the opportunity costs of the interventions 
at the time of the study.
In the baseline case, a time horizon of 10 years 
was assumed, although results from years 1 and 
5 are also presented. A discounted rate of 3% was 
used for costs and effectiveness alike according 
to the recommendations from the Colombian 
methodology guide (12). A long-term time horizon 
is appropriate considering that health outcomes 
and costs do not occur only during the first year 
and it is important to include the effect of long-term 
outcomes in the estimation of expected costs and 
effects of the interventions evaluated.
The estimation of mean costs and QALYs for each 
alternative can lead to four possible scenarios (13): 
a) The intervention (ticagrelor) costs more than the 
control (clopidogrel) and produces less QALYs. In 
this case, we say that the intervention is ‘dominated’ 
by the control. 
b) Conversely, the intervention costs less than the 
control and produces more QALYs, that is, the 
intervention ‘dominates’ the control. 
c) The intervention costs more and generates more 
QALYs than the control, and 
d) The intervention costs less and generates fewer 
QALYs than the control. If neither the intervention nor 
comparator treatments are dominated (scenarios 
A and B), the incremental cost effectiveness ratio 
(ICER) can be calculated as the ratio of differential 
mean cost to differential mean QALYs, that is, 
Table 2. Effectiveness information utilized in models
Variable Value Distribution parameters Source
Transition probabilities
Probability of myocardial infarction, year 1, ticagrelor
Probability of stroke, year 1, ticagrelor
Probability of death, year 1, ticagrelor
Probability of myocardial infarction, year 1, clopidogrel
Probability of stroke, year 1, clopidogrel 
Probability of death, year 1, clopidogrel 
Probability of myocardial infarction, long term
Probability of stroke, long term
Utility weights
No event
Myocardial infarction
Stroke
Post-myocardial infarction stage
Post-stroke stage
RR to adjust mortality
RR mortality after myocardial infarction, year 1 
RR mortality after myocardial infarction, long term
RR mortality after stroke, year 1 
RR mortality after stroke, long term
0.0540
0.0134
0.0378
0.0638
0.0114
0.0476
0.031
0.015
0.842
0.779
0.703
0.821
0.703
5.84
2.21
7.43
2.07
n=504; N=9333
n=125; N=9333
n=353; N=9333
n=593; N=9291
n=106; N=9291
n=442; N=9291
NA
NA
α=28004,078; 
β=5254,922
α=1341,11861; 
β=5254,922
α=1467,80073; 
β=620,10927
α=83,55494391; 
β=18,21721676
α=101,64825; 
β=42,94385526
NA
NA
NA
NA
Wallentin, et al. (9)
Colombian patient data
from Access registry
Astra Zeneca (10)
Astra Zeneca (10)
RR: Relative risk
Table 3. Medication price per unit
Antiplatelets Unit Unit costs (COP) Total annual cost
Clopidogrel
Ticagrelor
Clopidogrel (maximum price according to the Ministry 
of Health Resolution 4316 from 2011)
mg
mg
mg
$ 34.38
$ 37.86
$ 71.83
$    948,796
$ 2,487,475
$ 1,982,508
Source: SISMED and AstraZeneca (for ticagrelor)
ICER= 
Mean Cost Intervention - Mean Cost Control
Mean QALYs Intervention - Mean QALYs Control
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Comparing the incremental costs and effectiveness 
of an intervention generates an estimated cost per 
QALY. Assuming that we have a decision maker 
with legitimacy and an exogenously defined budget 
constraint, then the decision maker can compare 
the cost-effectiveness of the intervention with the 
threshold cost per QALY (14). In Colombia, such 
threshold has not been explicitly defined, and 
the aim of this evaluation is not to develop an 
estimate of willingness to pay for health results. 
However, to interpret the results of this study, we 
resorted to the recommendation by the World 
Health Organization that an intervention can be 
considered cost-effective if the incremental cost-
effectiveness ratio is less than three times the per-
capita gross domestic product, which corresponded 
to COP$ 36,143,349 in 2010.
Both probabilistic and deterministic sensibility 
analyses were conducted to determine the impact 
of uncertainty on the results. With regard to the 
price of clopidogrel, a deterministic sensitivity 
analysis was conducted using the maximum 
reimbursement price stipulated by the Colombian 
government (Resolution 4316 from 2011). We also 
performed a sensitivity analysis for the discount 
rate (0% and 5%).
For the probabilistic analysis, the cost for each 
of the outcomes was represented by a triangular 
distribution, which is a continuous distribution 
function used in situations where not very much 
information is available regarding the distribution 
of variables. Specifically, it is necessary to define 
three values: the minimum expected value, the 
mode, and the maximum expected value. To 
estimate each of these values, we considered 
the different percentages for contracting health 
services mentioned above (table 4).
Following standard practice, we used a beta distri-
bution to represent transition probabilities and utility 
weights. This distribution generates values between 
0 and 1 and, therefore, it is adequate to represent 
probabilities and utility weights (particularly in this 
case, where we did not have health states that 
generate negative utility weights).
Results of probabilistic sensitivity analysis are 
shown as cost-effectiveness acceptability curves 
(CEAC). The CEAC is derived from the joint density 
of incremental costs and incremental effects and 
shows the probability that any strategy is cost 
effective given the data, i.e., it has the highest net 
benefit, for different values of the threshold. All 
calculations were conducted using TreeAge Pro 
2009® software.
As we did not make any kind of intervention or 
modification in the biological, physiological or 
social variables of the individuals under analysis, 
this research was considered a project with no risk 
according to Resolution 8430 of the Ministerio de 
Salud (15), and, therefore, no informed consent 
or approval by an ethics committee on human 
research was required. 
Results
In the base case and with a time horizon of 10 years, 
using ticagrelor involved an additional cost of COP$ 
2,033,825 and an increase of 0.072 QALYs, thus 
generating an ICER of COP$ 28,411,503, which 
means that the treatment with ticagrelor would be 
a cost-effective strategy for the Colombian health 
system. The results are sensitive to changes in 
the time horizon and in the unit cost of clopidogrel 
(table 5). 
With regards to the time horizon, the cost per QALY 
gained was COP$ 244,567,477 considering only the 
cost and effectiveness of the first year. This value 
decreased to COP$ 20,756,184 per QALY gained 
when the time horizon was 20 years. Regarding 
the price of clopidogrel, the cost per QALY gained 
decreased to COP$ 11,321,457 when we used 
the maximum regulated price of clopidogrel and 
assumed a time horizon of 10 years.
Results of probabilistic sensitivity analysis are 
shown in figure 2 where it is clear that ticagrelor 
is generally associated with higher costs, but the 
Table 4. Costs of outcomes considered in the model
Outcome Minimum (ISS fees + 25%, 
conventional stent)
Mode (ISS fees + 30%, 
conventional stent)
Maximum (ISS fees + 48%, 
medicated stent)
Myocardial infarction
Cost of cardiac rehabilitation program
Stroke 
Post-stroke
$ 8,431,277
$    815,906
$ 2,143,076
$    335,076
$ 8,579,284
$    848,543
$ 2,219,670
$    346,221
$ 12,878,934
$      966,033
$   2,495,412
$      386,343
ISS: Instituto de Seguro Social 
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$0M $22M $44M $66M $88M
difference in effectiveness is subject to a greater 
uncertainty. However, for a threshold equivalent 
to three times the Colombian per-capita gross 
domestic product, the probability of ticagrelor 
being a cost-effective strategy was close to 75% 
and approached 1 as the threshold neared 80 
million (figure 3).
The conclusions were similar in the model that 
considered the probability of new cardiovascular 
events in the long term (table 6).
Table 5. Deterministic sensibility analysis: Time horizon, price of clopidogrel, and discount ratio
Strategy Cost per 
patient
Incremental 
cost
Effectiveness Incremental 
effectiveness
C/E Incremental 
C/E ratio
Time horizon
1 year
Clopidogrel
Ticagrelor
5 years
Clopidogrel
Ticagrelor
10 years
Clopidogrel
Ticagrelor
Price of clopidogrel
$948.796
Clopidogrel
Ticagrelor
$1.982.508
Clopidogrel
Ticagrelor
Discount ratio
0%
Clopidogrel
Ticagrelor
5%
Clopidogrel
Ticagrelor
$ 1,670,802
$ 3,108,240
$ 3,132,499
$ 4,924,248
$ 4,068,434
$ 6,102,258
$ 4,068,434
$ 6,102,258
$ 5,291,817
$ 6,102,258
$ 4,441,479
$ 6,527,591
$ 3,861,266
$ 5,866,053
$ 1,437,438
$ 1,791,749
$ 2,033,825
$ 2,033,825
$    810,441
$ 2,086,112
$ 2,004,787
0.798 QALY
0.804 QALY
4.330 QALY
4.372 QALY
7.162 QALY
7.233 QALY
7.162 QALY
7.233 QALY
7.162 QALY
7.233 QALY
8.231 QALY
8.314 QALY
6.572 QALY
6.637 QALY
0.006 QALY
0.042 QALY
0.072 QALY
0.072 QALY
0.072 QALY
0.083 QALY
0.065 QALY
$ 2,094,575
$ 3,868.095
$    723,397
$ 1,126,233
$    568,083
$    843,638
$    568,083
$    843,638
$    738,907
$    843,638
$    539,574
$    785,112
$    587,548
$    883,807
$ 244,567,477
$   42,605,827
$   28,411,503
$   28,411,503
$   11,321,457
$   25,206,909
$   30,644,159
C/E: Cost effectiveness 
QALY: Quality-adjusted life-year
Figure 2. Simulation results 
$7,1M
$6,6M
$6,1M
$5,6M
$5,1M
$4,6M
$4,1M
$3,6M
6,850 QALY 7,050 QALY
Effectiveness
C
os
t
7,250 QALY 7,450 QALY
Clopidogrel Ticagrelor
Figure 3. Acceptability curve for the comparison between 
ticagrelor and clopidogrel
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Table 6. Ticagrelor vs. clopidogrel: Results at 5 and 10 years considering the probability of reinfarction
Time horizon Strategy Cost per 
patient
Incremental 
cost
Effectiveness Incremental 
effectiveness
C/E Incremental 
C/E ratio
5 years
10 years
Clopidogrel
Ticagrelor
Clopidogrel
Ticagrelor
$ 3,194,821
$ 4,840,904
$ 4,162,110
$ 5,943,761
$ 1,646.083
$ 1,781,650
4.329 QALY
4.372 QALY
7.159 QALY
7.232 QALY
0.043 QALY
0.073 QALY
$    738,073
$ 1,107,347
$    581,370
$    821,903
$ 38,258,072
$ 24,551,985
C/E: Cost effectiveness
QALY: Quality-adjusted life-year
Discussion 
The results of this economic analysis suggest that 
ticagrelor is a cost-effective strategy in Colombia 
and that it could be included in the health benefits 
plan of the country’s health system. This conclu-
sion is consistent across different scenarios and 
sensitivity analyses, although two variables may 
modify the results: The time horizon, and the annual 
cost of treatment with clopidogrel considered as 
appropriate by the decision-maker.
With regard to the time horizon, short-term results 
can underestimate the actual costs and benefits of 
the alternatives and can therefore lead to wrong 
decisions. Keeping this in mind, this study adopted 
a time horizon that was large enough to capture the 
effects of the technologies and long-term costs that 
can be more relevant to decision-makers. 
This analysis tried to incorporate the best available 
evidence regarding the effectiveness of ticagrelor 
for the treatment of the acute coronary syndrome. 
The results from the most important clinical trial 
comparing both medications were considered, 
as were results from Colombian studies. Using a 
Markov model, we estimated the expected long-
term impact of the interventions with the aim of 
including all the costs and consequences implied by 
the interventions that may be relevant to decision-
making. The results of this cost-effectiveness 
analysis are applicable to Colombia, but could 
be useful to other countries if the costs and utility 
weights are adjusted according to the clinical 
practice in a particular setting. 
Our conclusions coincide with those of several 
economic evaluations comparing ticagrelor and 
clopidogrel for acute coronary syndrome treatment 
(10,16-18). The studies suggest that, although 
ticagrelor was associated with higher costs, the 
reductions in mortality and morbidity result in its 
ICER falling below conventional threshold values, 
including those recommended by the World Health 
Organization. Moreover, some studies suggest 
that ticagrelor could be a dominant alternative over 
clopidogrel, as it offers more benefits to patients 
at a lower cost (19,20).
Our study has several limitations. First, the 
effectiveness data, in particular the transition 
probabilities, were taken from information available 
in published articles; however, Colombian patients 
were included in the studies and we can expect 
similar results for the Colombian population. 
Considering that the difference in effectiveness 
between the two alternatives is subject to consider-
able uncertainty, studies on ticagrelor performance 
in Colombian patients would be valuable to reduce 
such uncertainty.
Second, the utility weights for each health outcome 
were based on the UK valuation of the EQ-5D, but 
we do not feel this is inappropriate considering 
that we do not have valuations in Colombia for any 
instrument to measure health-related quality of life. 
To acknowledge this uncertainty, the utility weights 
were represented by probability distributions.
In conclusion, the results of this study suggest 
that ticagrelor is a cost-effective strategy for 
the treatment of patients with acute coronary 
syndrome in Colombia. Data on its performance 
in Colombian patients would be very valuable to 
reduce uncertainty and thus provide more accurate 
information to decisionmakers.
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